Amylyx Pharmaceuticals Q4 net loss beats estimates

Reuters03-03
<a href="https://laohu8.com/S/AMLX">Amylyx Pharmaceuticals</a> Q4 net loss beats estimates

Overview

  • Pharmaceutical firm's Q4 loss per share beat analyst expectations

  • Net loss for Q4 beat analyst estimates

  • Company expects cash runway to fund operations through 2028

Outlook

  • Company expects topline data from Phase 3 LUCIDITY trial in Q3 2026

  • Amylyx plans potential commercialization of avexitide in 2027

  • Company targets IND submission for AMX0318 in 2027

Result Drivers

  • AVEXITIDE DEVELOPMENT - Increased spending on avexitide for PBH offset decrease in R&D expenses

Company press release: ID:nBwbp8fZXa

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

Beat

-$0.30

-$0.36 (10 Analysts)

Q4 Net Income

Beat

-$33 mln

-$37.05 mln (9 Analysts)

Q4 Operating Income

Beat

-$36.61 mln

-$40.37 mln (10 Analysts)

Q4 Pretax Profit

Beat

-$32.95 mln

-$39.01 mln (6 Analysts)

Q4 Cash & Investments

$317 mln

Q4 Operating Expenses

$36.61 mln

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $20.00, about 30.7% above its March 2 closing price of $15.30

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment